Vitamin-C-megaskorbicka-liecba.pdf - Zdravie.sk

Vitamín C a megaskorbická liečba – zabudnutý poklad 380 / 436
Zdroje
[711] Park C H, Amare M, Savin M A, Hoogstraten B. Growth suppression of human leukemic cells in vitro by L-
ascorbic acid. Cancer Res. 1980 Apr;40(4):1062-5. PMID:6928398.
http://cancerres.aacrjournals.org/cgi/reprint/40/4/1062
[712] Yamafuji K, Nakamura Y, Omura H, Soeda T, Gyotoku K. Anti-tumor potency of ascorbic, dehydroascorbic, or
2,3- diketogulonic acid and their action on deoxyribonucleic acid. Z Krebsforsch Klin Onkol Cancer Res Clin
Oncol. 1971;76(1):1-7. PMID:4255588. DOI:10.1007/BF00304282.
[713] Yagashita K, Takahashi N, Yamamoto H, Jinnouchi H, Hiyoshi S, Miyakawa T. Effects of tetraacetyl-bisdehydroAA,
a derivative of ascorbic acid, on Ehrlich cells and HeLa Cells (human carcinoma cells). J Nutr Sci
Vitaminol (Tokyo). 1976;22(6):419-27. PMID:1022854.
[714] Benade L, Howard T, Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-
amino-1, 2, 4-triazole. Oncology 1969;23(1):33-43. PMID:5774953. DOI:10.1159/000224465.
[715] Holman RA. A method of destroying a malignant rat tumour in vivo, Nature. 1957 May 18;179(4568):1033.
PMID:13430783. DOI:10.1038/1791033a0.
[716] Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid
supplements in advanced human cancer. Chem Biol Interact. 1974 Oct;9(4):285-315. PMID:4430016.
DOI:10.1016/0009-2797(74)90019-2.
[717] Pauling L. Vitamin C and heart disease. Executive Health. 1978 Jan;14(4). Rancho Santa Fe, California,
92067.
[718] Bram S, Froussard P, Guichard M, Jasmin C, Augery Y, Sinoussi-Barre F, Wray W. Vitamin C preferential
toxicity for malignant melanoma cells. Nature. 1980 Apr 17;284(5757):629-31. PMID:7366735.
DOI:10.1038/284629a0.
[719] Noto V, Taper HS, Jiang YH, Janssens J, Bonte J, De Loecker W. Effects of sodium ascorbate (vitamin C) and
2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of
combined vitamin C and K3 action. Cancer. 1989 Mar 1;63(5):901-6. PMID:2914296.
[720] Halliwell B, Gutteridge JMC, eds. Free radicals in biology and medicine, 2nd edn. Oxford: Clarendon Press,
1989; 124. Novšie vydania: 2007, 704p. ISBN13: 978-0-19-856869-8. ISBN10: 0-19-856869-X.
[721] Hickey S, Roberts HJ. The Cancer Breakthrough, Lulu Press, 2007, 96pgs. ISBN 978-1-4303-2300-6.
[722] Tsao CS, Dunham WB, Leung PY. In vivo antineoplastic activity of ascorbic acid for human mammary tumor.
In vivo. 1988 Mar-Apr;2(2):147-50. PMID:2979831.
[723] Koch CJ, Biaglow JE. Toxicity, radiation sensitivity modification, and metabolic effects of dehydroascorbate
and ascorbate in mammalian cells. J Cell Physiol 1978 Mar;94(3):299-306. PMID:23385.
DOI:10.1002/jcp.1040940307.
[724] Cohen MH, Krasnow SH. Cure of advanced Lewis lung carcinoma (LL): a new treatment strategy.
Proceedings of AACR. 1987;28:416.
[725] Lupulescu A. Vitamin C inhibits DNA, RNA and protein synthesis in epithelial neoplastic cells. Int J Vitam
Nutr Res. 1991;61(2):125-9. PMID:1717395.
[726] Varga JM, Airoldi L. Inhibition of transplantable melanoma tumor development in mice by prophylactic
administration of Ca-ascorbate. Life Sci. 1983 Apr 4;32(14):1559-64. PMID:6835004.
[727] Pierson HF, Meadows GG. Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor
activity against pigmented B16 melanoma. Cancer Res. 1983 May;43(5):2047-51. PMID:6831435.
http://cancerres.aacrjournals.org/cgi/reprint/43/5/2047.pdf
[728] Chakrabarti RN, Dasgupta PS. Effects of ascorbic acid on survival and cell-mediated immunity in tumor
bearing mice. IRCS Med Sci. 1984;12:1147-8.
[729] Duconge J, Miranda-Massari JR, González MJ, Taylor PR, Riordan HD, Riordan NH, Casciari JJ, Alliston K.
Vitamin C Pharmacokinetics after Continuous Infusion in a Patient with Prostate Cancer. Ann
Pharmacother. 2007 Jun;41(6):1082-3. Epub 2007 May 22. PMID:17519294. DOI:10.1345/aph.1H654.
http://www.theannals.com/cgi/content/full/41/6/1082
[730] Morishige F, Murata A. Prolongation of survival times in terminal human cancer by administration of
supplemental ascorbate. J Int Acad Prev Med. 1979;5:47-52.
[731] Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by
administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl. 1982;23:103-13. PMID:6811475.
[732] Riordan HD, Jackson JA, Schultz M. Can study: high-dose intravenous vitamin C in the treatment of a patient
with adenocarcinoma of the kidney. J Ortho Med. 1990;5:5-7.
[733] Cameron E, Baird GM. Ascorbic Acid and Dependence on Opiates in Patients with Advanced Disseminated
Cancer. J Int Res Communic. 1973;1(6):33.
[734] Cameron E, Campbell A. Innovation vs quality control: an "unpublishable" clinical trial of supplemental
ascorbate in incurable cancer. Med Hypotheses. 1991 Nov;36(3):185-9. PMID:1787807.
[735] Campbell A, Jack T, Cameron E. Reticulum cell sarcoma: two complete 'spontaneous' regressions, in
response to high-dose ascorbic acid therapy. A report on subsequent progress. Oncology 1991;48(6):495-7.
PMID:1749589.
[736] Hoffer J. Nutrients as Biologic Response Modifiers. Adjuvant Nutrition in Cancer Treatment. Ed. P. Quillin &
R. M. Williams. 1992 Symposium Proceedings, Cancer Treatment Research Foundation and American College
of Nutrition, Cancer Treatment Research Foundation, 3455 Salt Creek Lane, Suite 200, Arlington Heights, IL
60005-1090, 1993.
[737] Cameron E. Protocol for the use of vitamin C in the treatment of cancer. Med Hypotheses. 1991
Nov;36(3):190-4. PMID:1787808.
[738] Wirth A. [Therapeutic procedures for modifying the rate of flow of aqueous humor. II. Administration of
ascorbic acid in case of absent postoperative formation of the anterior chamber.] Boll Ocul. 1957 Feb;36(2):87-
90. Italian. PMID:13460039.